ABSTRACT

Objective: The role of systemic and chronic inflammatory processes in the pathophysiology of rheumatic heart valve disease is well known. The neutrophil-to-lymphocyte ratio (NLR) was shown to be an indicator of systemic inflammation. In this study, we aimed to investigate relationship between NLR as a marker of systemic inflammation and rheumatic mitral valve stenosis (RMVS).

Methods: This is a retrospective study. Among patients who underwent transthoracic echocardiography between January 2008-March 2013, 314 patients with RMVS were included retrospectively in the study. The control group included 57 healthy persons who underwent transthoracic echocardiography during the study period. Basal characteristics and NLR were compared between the two groups. Independent predictors of RMVS were determined by logistic regression analysis.

Results: Basal characteristics were similar among the groups (age, 50.2±14.2 vs. 49.2±13.0, p=0.60). The NLR was significantly higher in patients with RMVS [2.9 (0.6-13.0) vs. 2.1 (0.7-5.8), p<0.001]. Besides, C-reactive protein (CRP) was also higher in the RMVS group [5.99 (0.3-23.7) vs. 2.98 (0.6-6.3), p=0.001]. In the regression analysis, NLR (OR: 2.24, p=0.04), CRP (OR: 1.34, p=0.03), and left atrial diameter (OR: 1.21, p=0.001) were independent predictors of RMVS. In the correlation analysis, there was a significant positive correlation between NLR and CRP (r=0.43, p<0.001).

Conclusion: We found that NLR was significantly increased in RMVS. Furthermore, NLR was an independent predictor of the presence of RMVS in our study population. According to these findings, NLR can be used as a predictor of RMVS. Since it is an easily available and cheap method, it can easily be used in daily clinical practice. Increased NLR can also be a sign of ongoing chronic inflammation in patients with RMVS.

Keywords: rheumatic mitral valve disease, neutrophil-to-lymphocyte ratio, inflammation, C-reactive protein
2008-March 2013) of the Gazi University Medical Faculty Department of Cardiology were reviewed retrospectively, and patients with RMVS were included in the study. Among 1267 patients with RMVS, after evaluation according to the exclusion criteria, 314 patients remained for further analysis (our database consisted of 35,806 patients for this time period). Fifty-seven age- and gender-matched individuals who had normal echocardiographic findings were randomly selected from the same echocardiography database as the control group. Significant valvular heart disease except mitral valve disease, decompensated heart failure, presence of acute coronary syndrome, previous cardiac surgery, malignancy, renal or hepatic failure, acute or chronic infectious disease, autoimmune disease, anemia (definition of anemia according to the World Health Organization was a hemoglobin level of <12 g/dL in women or <13 g/dL in men), hematologic disease, and acute or chronic pulmonary disease were the exclusion criteria.

Transthoracic echocardiography (Vivid 7 system, 2.5- to 3.5-MHz transducer, GE-Vingmed Ultrasound AS, Horten, Norway) was performed by standard methods. Ejection fraction was measured by modified Simpson’s rule. Left atrial diameter (LAD) and left ventricular end-diastolic diameter (LVEDD) were measured in the parasternal long axis view by M-mode echocardiography. Mitral valve area was calculated by planimetric method in the parasternal short axis. Mitral stenosis (MS) was defined as follows: severe MS was a valve area of <1 cm², moderate MS was a valve area of 1.0-1.49 cm², and mild MS was a valve area of ≥1.5 cm² (12). According to this classification, the study included 70 patients with mild MS, 131 with moderate MS, and 113 with severe MS.

Laboratory analysis

Basal clinical characteristics and laboratory parameters were reviewed from the patients’ files. Laboratory parameters, including complete blood count (CBC), routine biochemistry, and cholesterol panel, taken from all study participants, were recorded. For CBC analysis, an automatic blood counter (A Cell-Dyn 3500, Abbot, IL, USA) was used. In our department, CRP levels were routinely studied after at least 8 hours of fasting. The blood samples were routinely centrifuged, and serum samples were collected. The CRP levels were analyzed with a Beckman Coulter Inc (Image 800, California, USA).

Statistical analysis

Statistical analysis was performed with SPSS 17.0 Statistical Package for Windows (SPSS Inc, Chicago, Illinois, USA). Continuous variables were given as the median±standard deviation, and categorical variables were defined as percentages. Data were tested for normal distribution using the Kolmogorov-Smirnov test. Categorical variables were compared with chi-square test. Student t-test or Mann-Whitney U test was used to compare continuous variables. Mean values were compared by ANOVA, followed by Tukey HSD test among different groups. Pearson’s correlation analysis was performed to define the correlation between hs-CRP levels and the (NLR). The receiver operating characteristics curve was used to demonstrate the sensitivity and specificity of NLR and the optimal cut-off value for predicting RMVS. In order to define the relationship between RMVS and possible confounding factors, univariate and multiple logistic regression analysis was performed. A p value of <0.05 was accepted as statistically significant.

Results

Basal characteristics are given in Table 1. Basal laboratory parameters are presented in Table 2. Lymphocyte count was lower in the RMVS group as compared to the control group [1.8 (0.4-4.6) vs. 2.2 (0.8-4.0), p<0.001]. NLR was significantly higher in the RMVS group [2.9 (0.6-13.0) vs. 2.1 (0.7-5.8), p<0.001]. The level of CRP was also higher in the RMVS group [5.99 (0.3-23.7) vs. 2.98 (0.6-6.3), p=0.001]. In the correlation analysis, it was seen that there was a significant positive correlation between NLR and CRP (r=0.43, p<0.001). When we excluded patients with atrial fibrillation, NLR in the RMVS group remained higher compared to NLR in the control group [2.91 (0.6-10.6) vs. 2.11 (0.7-5.8), p=0.001]. When the statistical analysis was performed after the exclusion of patients with hypertension, diabetes mellitus, coronary artery disease, and atrial fibrillation, NLR was still significantly higher in the RMVS group [2.89 (0.7-13.0) vs. 2.11 (1.1-5.0), p=0.003].

The NLR ratios were increasing in parallel to the severity of mitral stenosis; however, the difference did not reach statistical significance.

Table 1. Basal characteristics of groups

| Parameters          | Control n=57 | RMVS n=314 | P      |
|---------------------|--------------|------------|--------|
| Age, years          | 50.2±14.2    | 49.2±13.0  | 0.60*  |
| Female, n (%)       | 46 (80.7)    | 235 (74.8) | 0.34   |
| Hypertension, n (%) | 25 (43.8)    | 123 (39.1) | 0.59   |
| Diabetes mellitus, n (%) | 9 (15.7) | 43 (13.7) | 0.74   |
| Smoking, n (%)      | 12 (21.6)    | 43 (13.7)  | 0.15   |
| CAD, n (%)          | 11 (19.2)    | 49 (15.5)  | 0.46   |
| RAS blocker, n (%)  | 24 (42.1)    | 99 (31.6)  | 0.15   |
| Diuretic, n (%)     | 10 (17.5)    | 90 (28.6)  | 0.12   |
| CCB, n (%)          | 8 (14.0)     | 61 (19.5)  | 0.36   |
| β-blocker, n (%)    | 14 (24.5)    | 112 (35.6) | 0.11   |
| Statin, n (%)       | 14 (24.5)    | 54 (17.3)  | 0.23   |
| Aspirin, n (%)      | 18 (31.5)    | 112 (35.6) | 0.51   |
| OAD, n (%)          | 7 (12.2)     | 40 (12.8)  | 0.88   |
| Warfarin, n (%)     | 0 (0)        | 101 (32.2) | -      |
| LVEF, %             | 65.1±2.0     | 64.5±5.2   | 0.74   |
| LAD, cm             | 33.9 (26-41) | 42.9 (30-62) | <0.001* |
| LVEDD, cm           | 46.3 (40-54) | 46.7 (34-59) | 0.34*  |

Data are given as means±SD or %. CAD - coronary artery disease; CCB - calcium channel blocker; LAD - left atrial diameter; LVEDD - left ventricular end-diastolic diameter; LVEF - left ventricular ejection fraction; OAD - oral antidiabetic drug; RAS - renin-angiotensin system; RMVS - rheumatic mitral valve stenosis. *Chi-square test, Student t-test, Mann-Whitney U test.
significance. On the other hand, in the comparison of mitral stenosis groups with the control group, NLR in all mitral stenosis groups was significantly higher than in the control group \[2.66 (0.8-8.2), 2.92 (0.6-13.0), \text{ and } 3.01 (0.7-10.6) \text{ vs. } 2.10 (0.7-5.8), \text{ respectively, } p=0.002\] (Fig. 1).

In the univariate logistic regression analysis, mean platelet volume, lymphocyte count, LAD, NLR, and CRP were possible independent predictors of RMVS. In the multiple logistic regression analysis, LAD, NLR, and CRP remained independent predictors of RMVS (Table 3).

In the ROC curve analysis, an NLR level cutoff point of more than 2.3 predicted the presence of RMVS with a sensitivity of 60.8% and specificity of 77.2% (Fig. 2).

**Discussion**

In this study, we showed that NLR was significantly higher in patients with RMVS. Besides, we also found that CRP levels of patients with RMVS were higher than in the control group and that LAD was increased in patients with RMVS. Furthermore, NLR, CRP, and LAD were independent predictors of RMVS.

RMVS is one of the most serious complications of acute rheumatic fever, occurring in approximately 30% of patients (13). The pathogenic mechanism involved in this disease is believed to be an autoimmune process due to “antigen mimicry” (14). This pathophysiological mechanism is mainly based on antigenic similarity that is caused by an inappropriate cross-reaction between heart valves and M protein of group A streptococci. This reaction eventually leads to valvular damage in susceptible individuals (14). Since auto-reactivity has been thought to activate the complement system and start inflammatory reactions, inflammation takes a crucial role in this cross-reaction (15). CRP is a well-known inflammation marker. In their study, Gölbaşı et al. (4) showed that the CRP level in chronic rheumatic valve

**Table 2. Laboratory parameters of the study groups**

| Parameters               | Control n=57 | RMVS n=314 | \(^p\) |
|-------------------------|-------------|------------|------|
| Hemoglobin, g/dL        | 13.6 (12.0-16.5) | 13.4 (12.0-16.5) | 0.38* |
| Platelets, \(10^9/\text{mm}^3\) | 246.7 (136-487) | 233.4 (110-503) | 0.20* |
| Mean platelet volume, fL | 8.2±2.0 | 8.7±1.4 | 0.117 |
| White blood cell, \(10^9/\text{mm}^3\) | 7.5 (3.1-11.4) | 7.6 (2.5-12.9) | 0.64* |
| Neutrophils, \(10^9/\text{mm}^3\) | 4.4 (1.4-7.7) | 4.7 (0.8-10.3) | 0.49* |
| Lymphocytes, \(10^9/\text{mm}^3\) | 2.2 (0.8-4.0) | 1.8 (0.4-4.6) | <0.001* |
| Monocytes, \(10^9/\text{mm}^3\) | 0.5±0.2 | 0.6±0.2 | 0.86 |
| NLR                     | 2.1 (0.7-5.8) | 2.9 (0.6-13.0) | <0.001* |
| Creatinine, mg/dL       | 0.77±0.2 | 0.79±0.2 | 0.29 |
| CRP, mg/dL              | 2.98 (0.6-6.3) | 5.99 (0.3-23.7) | 0.001* |
| Total cholesterol, mg/dL | 196.2±38.2 | 188.0±36.1 | 0.16 |
| HDL-cholesterol, mg/dL  | 47.9±11.3 | 45.4±10.5 | 0.12 |
| LDL-cholesterol, mg/dL  | 122.9±32.8 | 116.3±28.0 | 0.17 |
| Triglyceride, mg/dL     | 140.5±80.0 | 132.0±63.1 | 0.76 |

CRP: C-reactive protein; HDL: high-density lipoprotein; LDL: low-density lipoprotein; NLR: neutrophil-to-lymphocyte ratio; RMVS: rheumatic mitral valve stenosis.

\(^*\)Student t-test, \(^\#\)Mann-Whitney U test

**Table 3. Multiple logistic regression analysis of rheumatic mitral valve stenosis**

| Variable                | \(^p\) | Odds ratio (95% CI) |
|-------------------------|------|---------------------|
| Mean platelet volume    | 0.29 | 0.81 (0.55-1.20)    |
| Lymphocytes             | 0.69 | 1.21 (0.47-3.12)    |
| Neutrophil-to-lymphocyte ratio | 0.04 | 2.24 (1.03-4.86)    |
| CRP                     | 0.03 | 1.34 (1.02-1.76)    |
| LAD                     | 0.001| 1.21 (1.08-1.36)    |

CRP: C-reactive protein; LAD: left atrial diameter.

\(^*\)Multiple logistic regression analysis

**Figure 1. Neutrophil-to-lymphocyte ratio according to presence and severity of rheumatic mitral valve stenosis**

\(^*\)ANOVA followed by Tukey test

**Figure 2. ROC curve analysis for neutrophil-to-lymphocyte ratio as a predictor of rheumatic mitral valve stenosis**

\(^*\)ROC analysis

Area under curve: 0.685
NLR in rheumatic mitral stenosis

1. Filgner CR, Reichenbach DD, Otto CM. Pathology and etiology of valvular heart disease. In: Otto CM, editor. Valvular Heart Disease. 2nd ed. Philadelphia: WB Saunders; 2004. p.30-3.

2. Marcus RH, Sareli P, Pocock WA, Barlow JB. The spectrum of severe rheumatic mitral valve disease in a developing country: Correlations among clinical presentation, surgical pathologic findings, and hemodynamic sequelae. Ann Intern Med 1994; 120: 177-83.

3. Olsson M, Thyberg J, Nilsson J. Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves. Arterioscler Thromb Vasc Biol 1999; 19: 1218-22. [CrossRef]

4. Gölbazi Z, Uçar O, Keleş T, Şahin A, Çağlı K, Çalışan A, et al. Increased levels of high sensitive C-reactive protein in patients with chronic rheumatic valve disease: evidence of ongoing inflammation. Eur J Heart Fail 2002; 4: 593-5. [CrossRef]

5. Yetkin E, Erbay AR, Ileri M, Turhan H, Balci M, Çehreli S, et al. Levels of circulating adhesion molecules in rheumatic mitral stenosis. Am J Cardiol 2001; 88: 1209-11. [CrossRef]

6. Gurmu HS, Bhatt DL, Lincoff AM, Tcheng JE, Kereiakes DJ, Kleiman NS, et al. Impact of preprocedural white blood cell count on long term mortality after percutaneous coronary intervention: insights from the EPIC, EPILOG, and EPISTENT trials. Heart 2003; 89: 1200-4. [CrossRef]

7. Kaya MG, Akpek M, Elçik D, Kalay N, Yarıkgülus M, Koç F, et al. Relation of left atrial spontaneous echocardiographic contrast in patients with mitral stenosis to inflammatory markers. Am J Cardiol 2012; 109: 851-5. [CrossRef]

8. Gillum RF, Mussolino ME, Madans JH. Counts of neutrophils, lymphocytes, and monocytes, cause-specific mortality and coronary heart disease: the NHANES-I epidemiologic follow-up study. Ann Epidemiol 2005; 15: 266-71. [CrossRef]

9. Margolis KL, Manson JE, Greenland P, Rodabough RJ, Bray PF, Safford M, et al. Leukocyte count as a predictor of cardiovascular events and mortality in postmenopausal women: the Women’s Health Initiative Observational Study. Arch Intern Med 2005; 165: 500-8. [CrossRef]
10. Horne BD, Anderson JL, John JM, Weaver A, Bair TL, Jensen KR, et al. Which white blood cell subtypes predict increased cardiovascular risk? J Am Coll Cardiol 2005; 45: 1638-43. [CrossRef]

11. Gibson PH, Cuthbertson BH, Croal RL, Rae D, El-Shafei H, Gibson G, et al. Usefulness of neutrophil/lymphocyte ratio as predictor of new-onset atrial fibrillation after coronary artery bypass grafting. Am J Cardiol 2010; 105: 186-91. [CrossRef]

12. Baumgartner H, Hung J, Bermejo J, Chambers JB, Evangelista A, Griffin BP, et al. Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. Eur J Echocardiogr 2009; 10: 1-25. [CrossRef]

13. Carapetis JR, McDonald M, Wilson NJ. Acute rheumatic fever. Lancet 2005; 366: 155-68. [CrossRef]

14. Guilherme L, Cunha-Neto E, Coelho V, Snitcowsky R, Pomerantzef PM, Assis RV, et al. Human heart-infiltrating T-cell clones from rheumatic heart disease patients recognize both streptococcal and cardiac proteins. Circulation 1995; 92: 415-20. [CrossRef]

15. Stollerman GH. Rheumatologic streptococci and autoimmunity. Clin Immunol Immunopathol 1991; 61: 131-42. [CrossRef]

16. Alyan O, Metin F, Kaçmaz F, Özdemir O, Maden O, Topaloğlu S, et al. High levels of high sensitivity C-reactive protein predict the progression of chronic rheumatic mitral stenosis. J Thromb Thrombolysis 2009; 28: 63-9. [CrossRef]

17. Chiu-Braga YY, Hayashi SY, Schafranski M, Messias-Reason IJ. Further evidence of inflammation in chronic rheumatic valve disease (CRVD): high levels of advanced oxidation protein products (AOPP) and high sensitive C-reactive protein. Int J Cardiol 2006; 109: 275-6. [CrossRef]

18. Zahorec R. Ratio of neutrophil to lymphocyte counts—rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy 2001; 102: 5-14.

19. Doğan M, Akyel A, Çimen T, Öksüz F, Çelik IE, Aytürk M, et al. Relationship between neutrophil-to-lymphocyte ratio and saphenous vein graft disease in patients with coronary bypass. Clin Appl Thromb Hemost 2013 May 7 [Epub ahead of print].

20. Öztürk S, Erdem A, Özlü MF, Ayhan S, Erdem K, Özyaşar M, et al. Assessment of the neutrophil to lymphocyte ratio in young patients with acute coronary syndromes. Turk Kardiyol Dern Ars 2013; 41: 284-9. [CrossRef]

21. Papa A, Emdin M, Passino C, Michelassi C, Battaglia D, Cocci F. Predictive value of elevated neutrophil-lymphocyte ratio on cardiovascular mortality in patients with stable coronary artery disease. Clin Chim Acta 2008; 395: 27-31. [CrossRef]

22. Sönmez O, Ertaş G, Becakız A, Taşal A, Erdoğan E, Asoğlu E, et al. Relation of neutrophil-to-lymphocyte ratio with the presence and complexity of coronary artery disease: an observational study. Anadolu Kardiyol Derg 2013; 13: 662-7.

23. Duffy BK, Gurm HS, Rajagopal V, Gupta R, Ellis SG, Bhatt DL. Usefulness of an elevated neutrophil to lymphocyte ratio in predicting long-term mortality after percutaneous coronary intervention. Am J Cardiol 2006; 97: 993-8. [CrossRef]

24. Turak O, Özcak F, İşleyen A, Başar FN, GÜl M, Yılmaz S, et al. Usefulness of neutrophil-to-lymphocyte ratio to predict in-hospital outcomes in infective endocarditis. Can J Cardiol 2013; 12: 1672-8. [CrossRef]

25. Onsrud M, Thorsby E. Influence of in vivo hydrocortisone on some human blood lymphocyte subpopulations. I. Effect on natural killer cell activity. Scand J Immunol 1981; 13: 573-9. [CrossRef]

26. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348: 138-50. [CrossRef]